{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Newborn&page=25",
    "query": {
      "condition": "Newborn",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 11256,
    "total_pages": 1126,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Newborn&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Newborn&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T10:11:20.408Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02582775",
      "title": "MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Thymoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Bone marrow infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Donor mesenchymal stem cell infusions",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 17,
      "start_date": "2016-03",
      "completion_date": "2023-07-26",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-06T10:11:20.408Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02582775"
    },
    {
      "nct_id": "NCT00786019",
      "title": "Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Exercise program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Ascorbic Acid (Vitamin C)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "30 Years to 55 Years"
      },
      "enrollment_count": 47,
      "start_date": "2008-05",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2023-07-12",
      "last_synced_at": "2026-11-06T10:11:20.408Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00786019"
    },
    {
      "nct_id": "NCT00331019",
      "title": "Rapid Detection of Group B Strep- 35-37 Week Study",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Group B Streptococcus Neonatal Sepsis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2006-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-12-15",
      "last_synced_at": "2026-11-06T10:11:20.408Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00331019"
    },
    {
      "nct_id": "NCT06450509",
      "title": "Proactive Speech and Language Intervention for Infants With Down Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Down Syndrome"
      ],
      "interventions": [
        {
          "name": "Babble Boot Camp",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Arizona State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Months",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "0 Months to 12 Months"
      },
      "enrollment_count": 60,
      "start_date": "2024-02-28",
      "completion_date": "2026-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-11-06T10:11:20.408Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06450509"
    },
    {
      "nct_id": "NCT04594031",
      "title": "US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Umbilical Cord Blood",
        "Hematopoietic Cell Proliferation"
      ],
      "interventions": [
        {
          "name": "ECT-001-CB (UM171-Expanded Cord Blood Transplant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ExCellThera inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "5 Years to 30 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-07-13",
      "completion_date": "2024-02-02",
      "has_results": false,
      "last_update_posted_date": "2022-07-05",
      "last_synced_at": "2026-11-06T10:11:20.408Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • San Francisco, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04594031"
    },
    {
      "nct_id": "NCT04372953",
      "title": "Positive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial).",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lung Injury",
        "Preterm Birth"
      ],
      "interventions": [
        {
          "name": "Positive End-Expiratory Pressure (PEEP)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Murdoch Childrens Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "23 Weeks",
        "maximum_age": "28 Weeks",
        "sex": "ALL",
        "summary": "23 Weeks to 28 Weeks"
      },
      "enrollment_count": 906,
      "start_date": "2021-05-04",
      "completion_date": "2028-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-11-06T10:11:20.408Z",
      "location_count": 4,
      "location_summary": "Little Rock, Arkansas • San Diego, California • Indianapolis, Indiana + 1 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04372953"
    },
    {
      "nct_id": "NCT04901702",
      "title": "Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Solid Tumor",
        "Recurrent Ewing Sarcoma",
        "Recurrent Hepatoblastoma",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Neuroblastoma",
        "Recurrent Osteosarcoma",
        "Recurrent Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Rhabdoid Tumor",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Recurrent Wilms Tumor",
        "Refractory Ewing Sarcoma",
        "Refractory Hepatoblastoma",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Neuroblastoma",
        "Refractory Osteosarcoma",
        "Refractory Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Rhabdoid Tumor",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Onivyde",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Months to 30 Years"
      },
      "enrollment_count": 90,
      "start_date": "2021-06-09",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-11-06T10:11:20.408Z",
      "location_count": 7,
      "location_summary": "Palo Alto, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04901702"
    },
    {
      "nct_id": "NCT01257737",
      "title": "To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urea Cycle Disorders"
      ],
      "interventions": [
        {
          "name": "HPN-100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 88,
      "start_date": "2010-10-04",
      "completion_date": "2017-02-16",
      "has_results": true,
      "last_update_posted_date": "2024-08-22",
      "last_synced_at": "2026-11-06T10:11:20.408Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Portland",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01257737"
    },
    {
      "nct_id": "NCT04140695",
      "title": "Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Tradipitant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanda Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 87,
      "start_date": "2019-10-21",
      "completion_date": "2020-10-14",
      "has_results": true,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-11-06T10:11:20.408Z",
      "location_count": 51,
      "location_summary": "Hoover, Alabama • Tempe, Arizona • Encino, California + 43 more",
      "locations": [
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04140695"
    },
    {
      "nct_id": "NCT07813039",
      "title": "A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "VX-581",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2026-09-23",
      "completion_date": "2026-10-27",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-06T10:11:20.408Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07813039"
    }
  ]
}